Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China.

Publisher: Medknow Publications Country of Publication: India NLM ID: 9516979 Publication Model: Print Cited Medium: Internet ISSN: 1998-4049 (Electronic) Linking ISSN: 13193767 NLM ISO Abbreviation: Saudi J Gastroenterol Subsets: MEDLINE

Publication: <2010-> : Mumbai : Medknow Publications
Original Publication: Riyadh : Saudi Gastroenterology Association, c1995-

Amoxicillin/*pharmacokinetics ; Helicobacter Infections/*drug therapy ; Helicobacter pylori/*drug effects ; Proton Pump Inhibitors/*pharmacokinetics ; Rabeprazole/*pharmacokinetics; Adult ; Amoxicillin/administration & dosage ; Amoxicillin/pharmacology ; Anti-Bacterial Agents/administration & dosage ; Bismuth/administration & dosage ; Breath Tests/methods ; China/epidemiology ; Clarithromycin/administration & dosage ; Drug Administration Schedule ; Drug Therapy, Combination/methods ; Female ; Gastritis/diagnosis ; Gastritis/drug therapy ; Gastritis/microbiology ; Helicobacter Infections/diagnosis ; Humans ; Male ; Middle Aged ; Peptic Ulcer/diagnosis ; Peptic Ulcer/drug therapy ; Peptic Ulcer/microbiology ; Proton Pump Inhibitors/administration & dosage ; Proton Pump Inhibitors/pharmacology ; Rabeprazole/administration & dosage ; Rabeprazole/pharmacology ; Treatment Outcome

Background\Aim: Quadruple daily administration of proton-pump inhibitor (PPI) therapy achieves potent acid inhibition, and combined with amoxicillin, with its pharmacodynamic and pharmacokinetic characteristics, may be efficient for Helicobacter pylori eradication. We compared the efficacy of two optimized high-dose dual therapies with a bismuth-containing quadruple regimen for treating H. pylori infection. Rabeprazole dosages for H. pylori eradication were also evaluated.
Patients and Methods: Treatment-naive and H. pylori-positive subjects were recruited and randomly apportioned to three treatment groups: Group A (n = 87), rabeprazole 10 mg plus amoxicillin 750 mg (4 times/day for 14 days); Group B (n = 87), rabeprazole 20 mg plus amoxicillin 750 mg (4 times/day for 14 days); and Group C (n = 89), bismuth-containing quadruple regimen consisting of rabeprazole 20 mg, bismuth 220 mg, amoxicillin 1000 mg, and clarithromycin 500 mg (2 times/day for 14 days). Four weeks after treatment discontinuation, patients were examined for H. pylori infection by 13C-urea breath test. The rates of adverse effects, compliance, and eradication were evaluated.
Results: Eradication rates in groups A, B, and C were 78.1, 81.6, and 84.3%, respectively, based on intention-to-treat analysis, or 79.1, 83.5, and 86.2%, according to per-protocol analysis. Rates of adverse events and compliance of the three groups were similar.
Conclusion: For treating H. pylori infection, optimized high-dose amoxicillin-PPI dual therapies failed to achieve high cure rates in China and held no advantage over a bismuth-containing quadruple regimen.

Helicobacter. 2014 Aug;19(4):312-8. (PMID: 24690010)
Eur J Clin Microbiol Infect Dis. 1995 Apr;14(4):353-5. (PMID: 7649202)
Antimicrob Agents Chemother. 1996 May;40(5):1327-8. (PMID: 8723498)
World J Gastroenterol. 2014 Jun 7;20(21):6400-11. (PMID: 24914361)
Gastroenterol Res Pract. 2016;2016:8547686. (PMID: 27247569)
Jundishapur J Microbiol. 2014 Jan;7(1):e8704. (PMID: 25147656)
Nat Clin Pract Gastroenterol Hepatol. 2008 Jun;5(6):321-31. (PMID: 18446147)
World J Gastrointest Pathophysiol. 2011 Jun 15;2(3):35-41. (PMID: 21860834)
J Dig Dis. 2014 Nov;15(11):622-7. (PMID: 25205201)
Antimicrob Agents Chemother. 1995 Aug;39(8):1859-61. (PMID: 7486933)
World J Gastroenterol. 2014 May 14;20(18):5283-93. (PMID: 24833858)
Recenti Prog Med. 2010 Jan;101(1):27-33. (PMID: 20391683)
Aliment Pharmacol Ther. 2016 Feb;43(4):514-33. (PMID: 26694080)
Aliment Pharmacol Ther. 2013 Nov;38(9):1129-37. (PMID: 24099474)
Clin Gastroenterol Hepatol. 2013 Jul;11(7):802-7.e1. (PMID: 23376004)
N Engl J Med. 1995 Oct 12;333(15):984-91. (PMID: 7666920)
Rev Gastroenterol Peru. 2009 Apr-Jun;29(2):158-70. (PMID: 19609331)
Pharmacotherapy. 2011 Mar;31(3):227-38. (PMID: 21361732)
Clin Pharmacol Ther. 2004 Oct;76(4):290-301. (PMID: 15470328)
Gut. 2015 Nov;64(11):1715-20. (PMID: 26338726)
Helicobacter. 2015 Feb;20(1):1-10. (PMID: 25382801)
Rev Latinoam Microbiol. 1997 Jan-Jun;39(1-2):9-31. (PMID: 10932712)
Gut. 2015 Sep;64(9):1353-67. (PMID: 26187502)
Lancet. 1984 Jun 16;1(8390):1311-5. (PMID: 6145023)
J Antimicrob Chemother. 1996 Jul;38(1):5-15. (PMID: 8858451)
Eur J Clin Pharmacol. 2007 Aug;63(8):743-9. (PMID: 17565490)
Aliment Pharmacol Ther. 2012 Oct;36(7):627-34. (PMID: 22882464)
Clin Gastroenterol Hepatol. 2015 May;13(5):895-905.e5. (PMID: 25460556)
Arch Immunol Ther Exp (Warsz). 2009 Jan-Feb;57(1):45-56. (PMID: 19219527)
World J Gastroenterol. 2014 Oct 28;20(40):14973-85. (PMID: 25356059)
Yale J Biol Med. 1996 May-Jun;69(3):301-16. (PMID: 9165699)
Helicobacter. 2010 Oct;15(5):460-6. (PMID: 21083752)

0 (Anti-Bacterial Agents)
0 (Proton Pump Inhibitors)
32828355LL (Rabeprazole)
804826J2HU (Amoxicillin)
H1250JIK0A (Clarithromycin)
U015TT5I8H (Bismuth)

Date Created: 20170923 Date Completed: 20180529 Latest Revision: 20201209

20231215

PMC5625363

10.4103/sjg.SJG_91_17

28937021